One page. Seven checks. Free today.

Analyst Targets

• BMO Capital: Downgraded to Market Perform from Outperform; price target $450
• TD Cowen: Maintains Buy rating (last published update August 5)
• Piper Sandler: Maintains Overweight; price target $457 (last published update August 20)
• Citi: Questions the Lp(a) therapeutic hypothesis itself; most cautious read on the street

What Just Happened

Amgen closed at $393.17 on Tuesday, down $44.06, on volume nearly three times its one-month average. The company did not report bad earnings, miss guidance, or face a regulatory setback. Its own Phase 3 data that day was positive. None of that mattered.

The selloff originated four trading days earlier, on September 4, when Novartis announced that pelacarsen, its Lp(a)-lowering drug originally developed with Ionis Pharmaceuticals, failed to meet its primary endpoint in the pivotal Lp(a)HORIZON Phase 3 trial despite significantly lowering Lp(a) levels in treated patients. The market spent the weekend digesting the implications, then marked down the entire drug class on Tuesday.

Because Amgen carries roughly 4% weight in the price-weighted Dow Jones Industrial Average, a single-stock decline of that magnitude contributed meaningfully to the index’s 628-point drop on the session. This was not just a broad market story. It was one science question, amplified through index mechanics.

The Science Problem

Pelacarsen’s failure introduced a distinction that now defines the entire Lp(a) investment debate: lowering Lp(a) levels in the blood does not automatically translate into reduced cardiovascular risk. That gap between biomarker reduction and clinical outcomes is exactly what Citi is now pulling on. If the biological hypothesis connecting Lp(a) to heart events is weaker than assumed, no drug in the class, regardless of how aggressively it lowers the marker, may deliver the outcomes that would support blockbuster revenue projections.

Amgen’s olpasiran is a quarterly-dosed siRNA therapy currently in the Phase 3 OCEAN(a)-Outcomes trial with 7,297 patients, with a primary completion date of March 31, 2028. At Amgen’s Q2 2026 earnings call, management differentiated olpasiran from pelacarsen, pointing to greater than 95% Lp(a) reduction and its every-12-week dosing schedule, and emphasized differences in outcomes-trial design. BMO noted that study design differences prevent a complete write-off of the Lp(a) target. Still, the firm wrote that Novartis’s failure raises the burden of proof for both olpasiran and Eli Lilly’s lepodisiran.

Eli Lilly fell roughly 2% on the same read-through. The XLV healthcare ETF, which holds both names as major positions, absorbed the dual-stock pressure even though Novartis is not a component.

What Survives in the Amgen Thesis

The Lp(a) program is a pipeline bet, not a revenue driver today. Amgen’s current commercial engine remains intact. Repatha, its PCSK9 inhibitor targeting a separate cholesterol pathway with proven cardiovascular outcomes, generated $876 million in Q1 2026 revenue on 34% year-over-year growth. TEZSPIRE and IMDELLTRA both produced positive Phase 3 data during the same broader news cycle, confirming that the pipeline outside of Lp(a) continues to execute.

The real financial risk sits at the intersection of olpasiran uncertainty and the patent cliff. Amgen has meaningful loss-of-exclusivity exposure across several major products over the next several years, including Prolia/XGEVA, Enbrel, Otezla, and Kyprolis. Olpasiran was the program most widely expected to help bridge that gap. Tuesday’s move reflects the market assigning a lower probability to that bridge.

Bull / Base / Bear

Bull: Olpasiran’s deeper Lp(a) reduction and differentiated trial design produce a positive OCEAN(a)-Outcomes readout in 2028. The class survives. MariTide delivers competitive obesity data. The stock recovers toward $450 and above.

Base: Olpasiran’s outcome data remain ambiguous until 2028. Amgen trades on its commercial execution: Repatha growth, biosimilar launches, and IMDELLTRA expansion carry the stock in the $380 to $430 range. BMO’s $450 target acts as a ceiling until clarity arrives.

Bear: Citi’s hypothesis skepticism proves correct. OCEAN(a)-Outcomes misses its primary endpoint in 2028, stripping out a key growth program that was expected to offset patent-cliff erosion. With loss-of-exclusivity pressure rising and no Lp(a) revenue materializing, the stock tests the mid-$300s.

Technical Overlay

Tuesday’s close at $393.17 represents a decisive break below the stock’s prior support band near $420, a level that had held through the BMO downgrade earlier in the session. The gap created by the open well below Friday’s close leaves overhead resistance clustered between $410 and $425. The 200-day moving average, which Amgen had traded comfortably above for most of its 34% year-to-date run, now becomes the first structural test on any attempted recovery.

Bottom Line

The question Tuesday’s session answered is simpler than it looks: how much of Amgen’s pre-close valuation was olpasiran? The answer was roughly $44 per share in a single day. What it did not answer is whether olpasiran will work. That verdict sits closer to 18 months to two years away. Until then, investors are holding a company with a strong commercial portfolio, a serious patent clock, and a pipeline centerpiece whose scientific premise is now contested by the street’s most cautious analysts. The IMDELLTRA data and Repatha growth are real. The Lp(a) question is genuinely open. Those two facts, not last week’s Novartis announcement alone, determine where this stock goes next.